BIO and ViS Research Help Streamline Pediatric Clinical Trials - - BioPharm International

ADVERTISEMENT

BIO and ViS Research Help Streamline Pediatric Clinical Trials


The Biotechnology Industry Organization (BIO) and ViS Research are expanding the Pediatric Clinical Research Group, launched in 2013, to include pediatric research sites. BIO and its member companies work with ViS to use its online analytics platform to evaluate global pediatric clinical research infrastructure, identify pediatric patient populations, and empower clinical research collaboration. The aim of the Pediatric Clinical Research Group is to help member companies more efficiently assess the global pediatric clinical research landscape and to engage sites more easily for pediatric clinical studies, according to a BIO press release.  The initiative also hopes to enable comprehensive mapping of the pediatric patient population with live feeds of local patient demographics, reduce the site burden from feasibility assessments, and decrease site start-up time.

“Our partnership with ViS Research Institute is helping streamline pediatric clinical research worldwide,” said BIO President and CEO Jim Greenwood in the press release. “ViS Analytics will help drug developers identify pediatric research sites, making it faster and easier to conduct pediatric clinical trials and, ultimately, deliver treatments and cures to children suffering from life threatening and debilitating diseases.”

“Innovative research approaches through analytics are needed to improve success in these most challenging pediatric drug development programs with more timely access for these new drugs in children,” said Dr. Ron Portman, Immediate Past Chair of BIO’s Pediatrics Committee.

Source: Biotechnology Industry Organization

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here